Nowadays, oncologists use a Gleason score for diagnosing & staging prostate cancer to determine the extent & aggressiveness of the disease as well as to the treatment for the patient.

seen from United States
seen from United States

seen from Slovakia

seen from Maldives
seen from Yemen
seen from Slovakia
seen from United States

seen from Malaysia

seen from Maldives

seen from Japan
seen from United States
seen from United States
seen from Brazil
seen from United States
seen from Japan

seen from Australia

seen from Germany
seen from China
seen from United States

seen from Australia
Nowadays, oncologists use a Gleason score for diagnosing & staging prostate cancer to determine the extent & aggressiveness of the disease as well as to the treatment for the patient.
State of the art in oncologic imaging of Prostate.
State of the art in oncologic imaging of Prostate.
State of the art in oncologic imaging of Prostate.
Author-Writer: Dror Nir, PhD
This is the third post in a series in which I will address the state of the art in oncologic imaging based on a review paper; Advances in oncologic imaging†‡that provides updates on the latest approaches to imaging of 5 common cancers: breast, lung, prostate, colorectal cancers, and lymphoma. This paper is…
View On WordPress
On the road to improve prostate biopsy
On the road to improve prostate biopsy
On the road to improve prostate biopsy Author-Writer: Dror Nir, PhD
Urologists are in constant search for a method that will improve the outcome of prostate biopsy, particularly when it comes to ruling-in and ruling-out clinically significant prostate cancer. As stated in my recent post – State of the art in oncologic imaging of Prostate;“The disease’s staging and related prognosis are…
View On WordPress
Higher Gleason Score and ADT Efficacy
A recent finding shows that men with a Gleason score of 9–10 prostate cancer may derive a smaller survival benefit from androgen deprivation therapy (ADT) compared with those with Gleason score of 8. However, in the men with a Gleason 8, ADT is associated with an approximately 20% decrease in all-cause mortality. These are among the findings of a new analysis published in European Urology.
This finding came from David Yang, MD, of Harvard Medical School and the Harvard Radiation Oncology Program in Boston, and colleagues who conducted a retrospective study of more than 20,000 men from the National Cancer Database (NCDB).
All individuals they evaluated had localized or locally advanced, Gleason score 8–10 prostate cancer who received external beam radiation therapy (EBRT) between 2004 and 2012. In this cohort, 78% of men with Gleason score 8 disease and 87% of men with Gleason 9–10 disease had ADT.
After conducting a multivariable analysis, Yang et al. found that ADT was associated with a significant improvement in overall survival for men with a Gleason score of 8 but not for men with a Gleason score of 9–10. Also, a higher Gleason score (8, 9, or 10) was associated with a decreasing benefit from ADT. However, the authors cautioned that the study is limited by the relatively short follow-up of a median of 4.0 years.
Based on the results of the study, intensification multiple treatment modalities of therapy should be considered for men with prostate cancer with a Gleason score of 9–10, the authors concluded. They also encourage the enrollment of such men in clinical trials or potentially adding novel anti-androgens or docetaxel. Both of these therapies have been shown to be effective in castration-resistant and castration-sensitive settings, according to the authors.
Neil Desai, MD, who is an assistant professor of Radiation Oncology at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas, said this is a provocative study that contradicts the commonly held belief that ADT improves outcomes in high-grade prostate cancer, irrespective of specific grade.
Prostate treatment at Apollo Spectra Hospital. Laser Prostatectomy is the surgical removal of the abnormalities in the prostate gland.
Low levels of vitamin D in men linked to aggressive Prostate Cancer
Low levels of vitamin D in men linked to aggressive Prostate Cancer
Low levels of vitamin D in men can predict aggressive prostate cancer identified at the time of surgery, new research has found. The finding is important because it can offer guidance to men and their doctors who may be considering active surveillance, in which they monitor the cancer rather than remove the prostate. “Vitamin D deficiency may predict aggressive prostate cancer as a biomarker,”…
View On WordPress
Topics in Pathology
Topics in Pathology
Larry H Bernstein, MD, FCAP, Curator
LPBI
Special Issues from Medscape Pathology
Journal of Clinical Pathology
Hospital Autopsy: Endangered or Extinct?
Angus Turnbull; Michael Osborn; Nick Nicholas
Disclosures
J Clin Pathol. 2015;68(8):601-604.
Abstract
Aim To determine the hospital autopsy rate for the UK in 2013.
Methods A study of data from a ‘Freedom of Information’…
View On WordPress
Urological Cancers of Men
Urological Cancers of Men
Larry H. Bernstein, MD, FCAP, Reporter, Curator
Leaders in Pharmaceutical Intelligence
http:pharmaceuticalintelligence.com/1/21/2015/larrybern/Urological Cancers of Men
Urological Cancers of Men
Impact of the U.S. Preventive Services Task Force Recommendations Against PSA Screening on Prostate Biopsy and Cancer Detection Rates.
B Bhindi, M Mamdani, GS Kulkarni, A Finelli, RJ Hamilton, J…
View On WordPress